A detailed history of Aevitas Wealth Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Aevitas Wealth Management, Inc. holds 4,896 shares of ALNY stock, worth $1.31 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
4,896
Previous 4,727 3.58%
Holding current value
$1.31 Million
Previous $946,000 22.94%
% of portfolio
0.69%
Previous 0.71%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 24, 2023

BUY
$185.53 - $241.31 $31,354 - $40,781
169 Added 3.58%
4,896 $0
Q2 2022

Jul 22, 2022

SELL
$120.42 - $169.29 $87,906 - $123,581
-730 Reduced 13.38%
4,727 $689,000
Q1 2021

Apr 29, 2021

BUY
$126.83 - $175.69 $5,073 - $7,027
40 Added 0.74%
5,457 $770,000
Q3 2020

Oct 22, 2020

SELL
$121.19 - $165.49 $60,595 - $82,745
-500 Reduced 8.45%
5,417 $789,000
Q2 2020

Jul 29, 2020

SELL
$104.21 - $156.44 $74,510 - $111,854
-715 Reduced 10.78%
5,917 $876,000
Q3 2019

Oct 21, 2019

SELL
$70.9 - $87.82 $11,131 - $13,787
-157 Reduced 2.31%
6,632 $533,000
Q2 2019

Jul 26, 2019

SELL
$65.86 - $92.79 $13,172 - $18,558
-200 Reduced 2.86%
6,789 $493,000
Q1 2019

May 09, 2019

SELL
$72.76 - $93.45 $11,423 - $14,671
-157 Reduced 2.2%
6,989 $653,000
Q4 2018

Feb 14, 2019

SELL
$62.67 - $88.33 $6,267 - $8,833
-100 Reduced 1.38%
7,146 $521,000
Q2 2018

Aug 10, 2018

SELL
$88.31 - $107.8 $26,493 - $32,340
-300 Reduced 3.98%
7,246 $714,000
Q1 2018

May 15, 2018

SELL
$115.92 - $148.54 $34,776 - $44,562
-300 Reduced 3.82%
7,546 $899,000
Q4 2017

Feb 13, 2018

BUY
$114.49 - $139.98 $898,288 - $1.1 Million
7,846
7,846 $997,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $32.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Aevitas Wealth Management, Inc. Portfolio

Follow Aevitas Wealth Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aevitas Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Aevitas Wealth Management, Inc. with notifications on news.